Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Eli Lilly gets green light to market Mounjaro for heart attacks and strokes in the US

31 August 2026 · By · Wire by Fusion42

Published

31 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at medwatch.com →

◆ Verified

Fusion42 · 31 August 2026 · Fusion42 review

The US regulatory authority has approved Eli Lilly's Mounjaro for preventing heart attacks and strokes in adults with type 2 diabetes at high cardiovascular risk.

This Wire brief sits within Fusion42's coverage of Biotech, and 20 sources have reported it between 28 Aug 2026 and 1 Sep 2026.

◆ ◆ The Wire takeaway

Your cardiovascular drug development just gained a direct competitor from Eli Lilly's Mounjaro approval for heart attack and stroke prevention. Reassess your market positioning and clinical focus immediately.

◆ Coverage

20 sources · first reported 28 Aug 2026 · latest 1 Sep 2026

◆ Topics

Biotecheli-lillymounjarodrug-approvalcardiovasculartype-2-diabetes